SC grills Sebi over lingering probe against Sandesara brothers despite Rs 5,100 cr settlement

Regulatory oversight is critical for market integrity. Inconsistencies or prolonged investigations, even after settlements, can raise questions about the efficiency and fairness of the regulatory framework.

• •Supreme Court scrutinised Sebi's ongoing actions against directors of Sterling Biotech.
• •This follows a ₹5,100 crore settlement payment by the directors.
• •The court had earlier invalidated all related cases.
• •Sebi's investigation concerns suspected routing of funds.
• •Risk flag: Regulatory uncertainty